Journal for ImmunoTherapy of Cancer (Nov 2023)

330 Combination therapy with stem cell derived natural killer cells and monoclonal antibodies leads to potent ADCC through engagement of endogenouse CD16

Jan Spanholtz,
Monica Raimo,
Nina Lamers-Kok,
Didem Özkazanc,
Daniëlle Steenmans,
Amanda van Vliet,
Anna-Maria Georgoudaki,
Adil Duru,
Denise Vodegel

Affiliations

Jan Spanholtz: Glycostem Therapeutics, Oss, Netherlands
Monica Raimo: Glycostem Therapeutics, Oss, Netherlands
Nina Lamers-Kok: Glycostem Therapeutics, Oss, Netherlands
Didem Özkazanc: Glycostem Therapeutics, Oss, Netherlands
Daniëlle Steenmans: Glycostem Therapeutics, Oss, Netherlands
Amanda van Vliet: Glycostem Therapeutics, Oss, Netherlands
Anna-Maria Georgoudaki: Glycostem Therapeutics, Oss, Netherlands
Adil Duru: Glycostem Therapeutics, Oss, Netherlands
Denise Vodegel: Glycostem Therapeutics, Oss, Netherlands

DOI: https://doi.org/10.1136/jitc-2023-SITC2023.0330
Journal volume & issue: Vol. 11, no. Suppl 1

Abstract

No abstracts available.

Published in Journal for ImmunoTherapy of Cancer

ISSN: 2051-1426 (Online)
Publisher: BMJ Publishing Group
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://jitc.bmj.com

About the journal